Dr. Krasner is an endocrinologist and joined as our Chief Medical Officer in June 2018. Prior to Crinetics, he was a Senior Medical Director at Shire Pharmaceuticals where he served as Global Development Lead for Natpara®, the first recombinant human intact parathyroid hormone treatment for hypoparathyroidism. Prior to Shire, Dr. Krasner worked at Biodel and Pfizer conducting clinical research at various stages of development in diabetes and obesity.
He obtained both his undergraduate and M.D. degrees from Northwestern University and received his clinical training in Internal Medicine and Endocrinology at Johns Hopkins University.